Healthinn
Project dates
Full title of the project:
NeuroHand. THE FIRST TABLET SOLUTION FOR THE NEUROLOGICAL POST-STROKE REHABILITATION OF THE MOST FUNCTIONAL BODY SEGMENT, THE HAND
Short name of the project:
NEUROHAND
Date of the award:
23/08/2020
Project duration:
9 months
Company:
Healthinn
Country:
Spain
Company Website:
https://www.linkedin.com/company/healthinn/about/
Project partners:
Abstract
“According to scientific evidence, stroke is one of the most resource-intensive illnesses, costing the world $33.9 million annually, 70% of which is spent on hospital services. In Canada, an estimation has been made of the costs per stroke patient during the first year, determining that they reach 75,000 dollars, and a large part of these costs correspond to hospitalization and rehabilitation. Due to the huge expense involved in the health care of these patients, it is essential to find cost-effective approaches that optimize both the resources allocated to this pathology and the quality of care provided.
In this case, intensive neurorehabilitation of the upper limb in neurological patients is the main treatment for their recovery of functionality and autonomy. However, current evidence highlights that it is impossible to perform this type of high-dose rehabilitation in current healthcare systems due to a large number of patients and the scarcity of human and logistical resources.
NeuroHand is a unique Human-Computer software solution based on scientific evidence that provides end-to-end novel rehabilitation services to patients with a neurological affectation of hand, wrist, and fingers. NeuroHand adapts the latest evidence in upper limb neuro-rehabilitation to offer treatment and support both in the clinic and at home for the approach and recovery of functionality in the neurological patient, providing an affordable and easily accessible format for intensive neuro-rehabilitation through a Tablet app and monitored by the healthcare professional. Software as a Medical Device (SAMD) is presented as a solution to current problems of devices regarding scalability and penetration, to reach the maximum number of patients regardless of socioeconomic level.”
NEUROHAND